Navigation Links
ITMN in Medical News

Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis

...orced Vital Capacity is among strongest predictors of one-year mortality - SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today reported that results of a study assessing the relationship between various measures of clinical status and the risk of death in patients with...

InterMune to Present at Cowen Health Care Conference

... BRISBANE, Calif., March 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Cowen and Company 29th Annua...

InterMune Reports Results from Triple Combination Study of ITMN-191

...gin in Q2 2009 - - Conference call today at 8:30 a.m. EST - BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today reported top-line results from all six completed dosage cohorts of its Phase 1b clinical trial of ITMN-191 (R7227) in combination with standar...

InterMune to Present at Thomas Weisel Partners Healthcare Conference

... BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in ...

InterMune to Present at the 2008 Wachovia Healthcare Conference

... BRISBANE, Calif., Jan. 23 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the 2008 Wachovia Healthcare Conference in Bost...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...ics Inc RESP 157248157.2 Theravance Inc THRX 212837798.5 Intermune Inc itmn 296874543.2 Sepracor Inc. SEPR 385036542.3 Nektar Therapeutics NKTR 1272671080 Encys...
ITMN in Medical Technology

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...eported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) reported that results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were present...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...nts with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: itmn ) and Pharmasset (Nasdaq: VRUS ) today announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) c...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...dy - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that results from a 14-day Phase 1b clinical study of ITMN-191 (R7227) in combination with the current standard of care were present...

InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3

... BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market ...

InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191

... BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-d...

InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009

... BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combinati...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: itmn ) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus ...

InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C

...nued development in treatment-experienced patients - BRISBANE, Calif., May 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination wi...

InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA

...s Shionogi Phase 3 results on pirfenidone - BRISBANE, Calif., May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that its program for the development of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) has received "Fast Trac...

InterMune Announces Progress on Pirfenidone in IPF

...ne study now available on ATS website - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulm...
ITMN in Biological Technology

InterMune to Present at Canaccord Adams Conference

... BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second q...

InterMune to Release Second Quarter Financial Results on August 6

... BRISBANE, Calif., July 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release second quarter 2009 financial results on Thursday, August 6, 2009 at 4:00 p.m. Eastern time. A live conference...

InterMune to Present at Goldman Sachs Healthcare Conference

... BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Globa...

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

... - Conference call and webcast Tuesday, May 19, 6 p.m. PDT - BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that an oral late-breaker presentation and two poster discussion presentations related to the company's pulmonology programs will be...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... data from 14-day triple combination study of ITMN-191 in HCV - BRISBANE, Calif. , April 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 o...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

... - Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that the innovative clinical study of protease inhibitor ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 ...

InterMune to Release First Quarter Financial Results on April 30

... BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference ...

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

... -- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Sat...

InterMune to Present at Canaccord Adams Hepatitis C Conference

... BRISBANE, Calif., April 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Canaccord Adams Hepatitis C Conference o...
Other Tags
(Date:8/20/2014)... Taking the widely used antibiotic clarithromycin may boost ... new study suggests. Because millions of people receive ... said the Danish researchers behind the study. However, they ... guidelines for the use of the drug should not ... heart expert wasn,t surprised by the finding, however. ...
(Date:8/20/2014)... According to a new market research report ... Crystal, Microblinds, Thermographic and Photochromics), by application (Architectural, ... geography - Global Forecast to 2014 - 2020", ... market was worth $1581.4 Million in 2013, and ... at an estimated CAGR of 20% from 2014 ...
(Date:8/20/2014)... Washington, D.C. (PRWEB) August 20, 2014 ... has received a five-year, $1.24 million Science Education ... of Health to support NAHN’s collaborative project with ... Models in Health Careers. , This collaborative NIH ... need for cultural and linguistic diversity among health ...
(Date:8/20/2014)... The report “Automotive Airbag and Seat Belt Market ... Geography - Trends and Forecasts 2014 - 2019”, ... and seatbelt market in terms of volume and ... the coming years as well as covers review ... challenges, legislation trends, market dynamics, competitive landscape, and ...
(Date:8/20/2014)... Oxnard dentist and noted international ... Art Institute, is presenting at the Spectrum Day Vancouver ... on All-on-4 dental implants in a presentation ... at 12:40 p.m. Sept. 20 at the Empire Landmark ... , “The All-on-4 procedure gives patients a set of ...
Breaking Medicine News(10 mins):Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 2Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 3
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome (NAS) ... difficult time going through withdrawal than others, but ... genetic and epigenetic (when genes are turned on ... potential factors, researchers at Boston University School of ... a first of its kind study to identify ...
(Date:8/19/2014)... in college biology and other science courses are ... ways, and now they have a new textbook ... Life Sciences," published this month by Princeton Press ... for Mathematical and Biological Synthesis (NIMBioS), teaches readers ... be used to explore and explain biological phenomena. ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
Other Contents